Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice

被引:21
|
作者
Bruggemann, Lois W. [1 ]
Schoenmakers, Saskia H. H. F. [1 ]
Groot, Angelique P. [1 ]
Reitsma, Pieter H. [1 ]
Spek, Arnold [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
FV Leiden; sepsis; inflammation; coagulation; animal experiments;
D O I
10.1097/01.CCM.0000228918.30931.E8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The factor V Leiden (FVL) mutation (Arg506Glu) results in the production of an FV protein that when activated is relatively resistant to inactivation by activated protein C and thereby leads to predisposition to thrombosis. The rather high prevalence of the FVL mutation in the general population prompted speculation about a potential survival benefit for individuals carrying the FVL allele. Indeed, both clinical and experimental animal data suggest that a heterozygous FVL genotype might protect against the lethal consequences of sepsis. We sought to confirm the survival advantage of heterozygous FVL mice in septic disease. Design. Controlled animal experiment. Setting: Academic research laboratory. Subjects: Wild-type, heterozygous, and homozygous FVL mice subjected to 1 X 10(4) live bacteria as model for septic peritonitis. Interventions. None. Measurements and Main Results. The intraperitoneal injection of E coli led to growth and dissemination of bacteria and provoked an inflammatory response as evident from elevated cytokine levels (interleukin-6, interleukin-10, and tumor necrosis factor-alpha), induced thrombin-antithrombin complex levels, increased granulocyte influx into the peritoneal cavity, liver necrosis, and adhesion of leukocytes to the vessel wall, resulting in approximately 50% mortality after 72 hrs. The FVL genotype had no significant effect on bacterial outgrowth, markers of inflammation (i.e., tumor necrosis factor-alpha levels of 152 [96.2-200],152 [99.7-1745], and 110 [99.7-177] pg/mL in peritoneal lavage fluid at t = 20 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), thrombin generation (i.e., thrombin-antithrombin complex levels of 19.9 (9.31-37.4],10.4 [6.55-15.8], and 12.6 (8.24-29.0] ng/mL in peritoneal lavage fluid at t = 6 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), and/or survival (50%, 36%, and 50% for wild-type, heterozygous, and homozygous FVL mice, respectively). Conclusions. The FVL allele has no beneficial effect in mouse septic peritonitis, and the general protective effect of FVL in sepsis needs further investigation.
引用
收藏
页码:2201 / 2206
页数:6
相关论文
共 50 条
  • [1] Role of the FV Leiden mutation in septic peritonitis assessed in FV Leiden transgenic mice
    Bruggemann, LW
    Schoenmakers, SN
    Groot, AP
    Reitsma, PH
    Spek, CA
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 89 - 89
  • [2] Detection of the Factor V Leiden mutation in septic patients
    Gorodnova, E.
    Grachev, S.
    Beloborodov, V.
    Malov, V.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S496 - S497
  • [3] Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation
    Ymir Saemundsson
    Signý Vala Sveinsdottir
    Henrik Svantesson
    Peter J. Svensson
    Journal of Thrombosis and Thrombolysis, 2013, 36 : 324 - 331
  • [4] Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Ymir
    Sveinsdottir, Signy Vala
    Svantesson, Henrik
    Svensson, Peter J.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 324 - 331
  • [5] Homozygous factor V Leiden and compound heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Y.
    Sveinsdottir, S., V
    Svantesson, H.
    Svensson, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 151 - 151
  • [6] Arterial thrombosis in mice with factor V Leiden mutation
    Sampram, Ellis S.
    Saad, Yasser
    Ouriel, Kenneth
    VASCULAR, 2008, 16 (01) : 31 - 34
  • [7] Factor v Leiden mutation and preeclampsia
    Rigó, J
    Nagy, B
    Fintor, L
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (04) : 853 - 853
  • [8] THE ROLE OF FACTOR V LEIDEN MUTATION IN OSTEONECROSIS OF THE HIP
    Boriel, G.
    Glueck, C.
    Freiberg, R. A.
    Jurantee, J.
    Abuchaibe, C.
    Khan, Z.
    Brar, A.
    Padda, J.
    Wang, P.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (04) : 746 - 746
  • [9] The Role of the Factor V Leiden Mutation in Osteonecrosis of the Hip
    Glueck, Charles J.
    Freiberg, Richard A.
    Boriel, Gail
    Khan, Zia
    Brar, Amanpreet
    Padda, Jagjit
    Wang, Ping
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2013, 19 (05) : 499 - 503
  • [10] Tamoxifen and the Factor V Leiden Mutation
    Cuzick, Jack
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (13) : 918 - U1